目的:探讨miRNA-221在非小细胞肺癌组织中的表达及其与预后的相关性。方法:回顾性收集分析南通大学附属医院2010年1月至2012年12月期间行完全切除术治疗的153例非小细胞肺癌患者的临床资料,同时应用RT-PCR检测患者组织标本miRNA-221的表达量,分析其与患者临床资料及总生存期(OS)的关系。结果:年龄、临床分期与miRNA-221表达存在相关性,P<0.05。单因素COX回归分析显示, 临床分期(OR=1.96,95%CI:1.14~2.67)、腺癌(OR=2.54,95%CI:1.77~5.12)、肿瘤大小(OR=1.33,95%CI:1.01~2.14)和miRNA-221(OR=3.07,95%CI:1.76~6.31)表达均是影响OS的危险因素;多因素COX回归分析显示,临床分期(OR=3.32,95%CI:1.67~7.05)和miRNA-221表达(OR=2.55,95%CI:1.41~4.85)是影响OS的独立危险因素。结论:miRNA-221高表达提示非小细胞肺癌患者OS较短,有望作为肺癌预后预测的分子标志物。 |
Objective:To investigate the expression of miRNA-221 in non-small cell lung cancer and its correlation with prognosis. Methods:the clinical data of 153 patients from January 2010 to December 2012 with non-small cell lung cancer who were treated by surgery were retrospectively analyzed, and the expression of miRNA-221 was detected by RT-PCR analysis, and the relationship between the clinical data and the overall survival(OS) of patients was analyzed. Results:there was a correlation between age, clinical stage and miRNA-221 expression with P<0.05. COX regression analysis showed that clinical staging (OR=1.96, 95%CI:1.14-2.67), adenocarcinoma (OR=2.54, 95%CI:1.77-5.12), tumor size (OR=1.33, 95%CI:1.01-2.14) and miRNA-221 expression (OR=3.07, 95%CI:1.76-6.31) were the risk factors of OS, clinical stage (OR=3.32, 95%CI:1.67-7.05) and miRNA-221 expression (OR=2.55, 95%CI:1.41-4.85) were independent risk factors of OS. Conclusion:miRNA-221 highly expresses in the short-lived patients with non-small cell lung cancer, and may be expected to be a molecular marker for predicting the prognosis of lung cancer. |
[1] 叶茂,陈跃磊,明镇寰.miRNA (microRNA)家族的研究进展[J].生物化学与生物物理进展,2003,30(3):370-375.
[2] BELL R E,KHALED M,NETANELY D,et al.Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1[J].The Journal of Investigative Dermatology,2014,134(2):441-451.
[3] XU Y,BRENN T,BROWN E R,et al.Differential expression of microRNAs during melanoma progression: MiR-200c,miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors[J].The British Journal of Cancer,2012,106(3):553-561.
[4] 庞新亚,高峰,权胜伟,等.miRNA-221和miRNA-222在肝细胞肝癌中的表达及临床意义[J].现代肿瘤医学,2014,22(12):2912-2915.
[5] 张春智,康春生,杨卫东,等.共抑制miR-221/222表达上调PUMA促进胶质瘤U251细胞凋亡的体外研究[J].中华神经外科杂志,2010,26(8):752-755.
[6] 杨晓,甘蓉,杨英梅,等.miRNA-221和miRNA-222对前列腺癌细胞PC-3的增殖、迁移及SIRT1表达的调控[J].检验医学,2014,12(5):446-451.
[7] 姜波,王玉明,段勇,等.肺癌组织中调控PUMA基因的miRNA筛查和MiR-221表达差异研究[J].现代检验医学杂志,2015,30(1):15-19.
[8] KIM J K,CHOI K J,LEE M,et al.Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer and microRNA-221 molecular beacon-conjugated nanoparticle[J].Biomaterials,2012,33(1):207-217.
[9] 吕俊杰,徐磊,许有涛,等.非小细胞肺癌组织miRNA-221表达及其与预后的关系研究[J].中国肺癌杂志,2014,17(3):221-225.
[10] IHLE M A,TRAUTMANN M,KUENSTLINGER H,et al.miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours[J].Mol Oncol,2015,9(7):1421-1433.
[11] 曾俊杰,孙凯,吴承堂,等.应用实时荧光定量PCR检测结直肠癌与癌旁组织中miRNA-221的差异表达状况[J].山东医药,2010,50(12):26-28.
[12] 侯丽丽,程冰,张旭东,等.TRAIL诱导黑色素瘤细胞中miRNA-221的表达[J].安徽医科大学学报,2011,46(2):120-124. |
